Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA

Rank in Stocks #19388
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.26
Last synced: 2026-11-18
Market Cap
$101.72M
Change (1 day)
-0.61%
Change (1 year)
-33.83%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Earnings for Heidelberg Pharma AG (HPHA)
Earnings in Aug 2026 TTM: $-31.34M
According to Heidelberg Pharma AG's latest financial reports, its current earnings (TTM) are $-31.34M. In 2025 the company earned $-47.82M, a decrease compared to its 2024 earnings of $-20.50M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Heidelberg Pharma AG from 2006 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-31.34M -34.46%
2025 $-47.82M 133.20%
2024 $-20.50M -7.47%
2023 $-22.16M 19.53%
2022 $-18.54M -37.41%
2021 $-29.62M 35.07%
2020 $-21.93M 96.21%
2019 $-11.18M -15.40%
2018 $-13.21M 1.19%
2017 $-13.06M 93.16%
2016 $-6.76M -1.83%
2015 $-6.88M -1.38%
2014 $-6.98M 1.92%
2013 $-6.85M -43.88%
2012 $-12.21M -34.77%
2011 $-18.71M -37.70%
2010 $-30.04M 57.45%
2009 $-19.08M -26.58%
2008 $-25.99M 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$4.76B -15,287.82%
US
$-2.73B 8,608.39%
US
$-4.02B 12,715.90%
AU
$2.79B -9,013.78%
BE
$1.50B -4,876.82%
NL

Questions about Heidelberg Pharma AG's net income

What is Heidelberg Pharma AG's net income?

Heidelberg Pharma AG's net income over the last twelve months is $-31.34M, as of Aug 2026.

What was Heidelberg Pharma AG's net income in 2025?

In 2025, Heidelberg Pharma AG's net income was $-47.82M, compared with $-20.50M in 2024.

How has Heidelberg Pharma AG's net income changed since 2020?

From 2020 to 2025, Heidelberg Pharma AG's net income was highest in 2022 ($-18.54M) and lowest in 2025 ($-47.82M).

How does Heidelberg Pharma AG's net income compare with similar companies?

Heidelberg Pharma AG's net income ($-31.34M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.